A phase 1 trial is currently examining the safety and preliminary efficacy of XmAb819, a BiTE that targets ENPP3 and CD3, for the treatment of advanced RCC in the refractory setting (NCT05433142). Here, ENPP3 is linked to renal cell carcinoma.